59 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
17
Ending by 2030
Jan 2027
Next term end
46
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2031 · Medium confidence
Also notable
Ends Dec 2036 · High confidence
Also notable
Ends Aug 2031 · High confidence
Also notable
Ends Feb 2031 · High confidence
Also notable
Ends Dec 2029 · High confidence
Also notable
Ends Nov 2029 · High confidence
Also notable
Ends Sep 2034 · High confidence
Also notable
Ends Apr 2036 · High confidence
Use of Proteases for Gluten Intolerance
US 9,498,520
The most cited patent in this portfolio, cited by 27 later US patents, top 25% of utility patents granted in 2016 in our data. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
Beta-Galactosidase Enzymes
US 11,512,299
Granted 2022. Computed term ends 2036.
Beta-Galactosidase Derived from Bacillus Circulans
US 9,516,888
Granted 2016 and renewed at every maintenance window due so far. Protection runs to 2031.
Mutant Enzyme and Application Thereof
US 8,883,434
Renewed at every maintenance window since the 2014 grant; no more fees are due before its term ends in 2031.
Method for Improvement of Foods Utilizing Beta-Amylase
US 8,895,088
Renewed at every maintenance window since the 2014 grant; no more fees are due before its term ends in 2029.
Beta-Amylase, Gene Coding Therefor and Manufacturing Method Thereof
US 8,486,682
Renewed at every maintenance window since the 2013 grant; no more fees are due before its term ends in 2029.
Modified ß-Galactosidase
US 10,465,219
A family of 5 related applications built on the 2019 grant. Protection runs to 2034.
Modified Lipase and Use Thereof
US 10,415,023
Granted 2019. Computed term ends 2036.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 27, 2026The maintenance fee for Stabilised Dry Protein Deamidase Composition (US 11,685,914) comes due Dec 27, 2026. Unpaid by Jun 28, 2027, it lapses early.
- 1 fee due Jan 28, 2027The maintenance fee for Beta-Amylase, Gene Coding Therefor and Manufacturing Method Thereof (US 9,090,886) comes due Jan 28, 2027. Unpaid by Jul 28, 2027, it lapses early.
- 1 fee due Feb 8, 2027The maintenance fee for Novel Lipase and Uses of the Same (US 11,718,837) comes due Feb 8, 2027. Unpaid by Aug 9, 2027, it lapses early.
- 2 fees due Mar 17 to 29, 2027 · next Mar 17
- 1 fee due Apr 13, 2027The maintenance fee for Beta-Amylase, Gene Coding Therefor and Manufacturing Method Thereof (US 9,157,074) comes due Apr 13, 2027. Unpaid by Oct 13, 2027, it lapses early.
- 1 fee due May 5, 2027The maintenance fee for Modified ß-Galactosidase (US 10,465,219) comes due May 5, 2027. Unpaid by Nov 5, 2027, it lapses early.
- 2 fees due Jun 5 to 22, 2027 · next Jun 5
- 3 fees due Jul 2 to 26, 2027 · next Jul 2
Recent changes
- Nov 6Assignment recorded on 1 record: Nagaki, Kakeru to Amano Enzyme Inc. Recorded Nov 6, 2026, executed Oct 30, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76665, frame 986.
- 2 of the patents on this record were granted since Aug 22, 2026
- 1 term has ended since Aug 22, 2026
- Oct 6 US 8,114,642 Method for Producing Vitamin K2 from Culture of Bacillus Natto · term ended
What they patent
The largest of its 46 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Beta-Galactosidase Enzymes | 3 in force | to Dec 2036 |
| Beta-Amylase, Gene Coding Therefor and Manufacturing Method Thereof | 3 in force | to Nov 2029 |
| Intestinal Flora Improvement Agent | 2 in force | to Jan 2038 |
| Modified Lipase and Use Thereof | 2 in force | to Apr 2036 |
| Modified ß-Galactosidase | 2 in force | to Sep 2034 |
| Saccharide Oxidase, and Production Method for Same and Use of Same | 2 in force | to Sep 2033 |
| Beta-Galactosidase Derived from Bacillus Circulans | 2 in force | to Aug 2031 |
| Mutant Enzyme and Application Thereof | 2 in force | to Feb 2031 |
| Use of Proteases for Gluten Intolerance | 2 in force | to Feb 2031 |
| Maltotriosyl Transferase and Use Thereof | 2 in force | to Mar 2030 |
| Stabilized Transglutaminase and Process for Production Thereof | 2 in force | to Jan 2029 |
| Microorganism with Improved Protein Productivity and Use Thereof | 1 in force | to Jun 2043 |
| Polypeptide Having Esterification Activity for L-Menthol And/Or Hydrolyzing Activity for L-Menthol Ester | 1 in force | to Dec 2042 |
| Collagenase Agent and Use Thereof | 1 in force | to Nov 2042 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,947,315 | Dairy Products and Method of Manufacturing the Same held by Amano Enzyme Inc. and Ajinomoto Co., Inc. In force · High confidence | In force | High confidence | |
| US 7,709,240 | Amp Deaminase Originating Streptomyces and Utilization Thereof In force · High confidence | In force | High confidence | |
| US 7,998,721 | Novel Diglycosidase and Gene Encoding the Same In force · High confidence | In force | High confidence | |
| US 9,217,141 | Stabilized Transglutaminase and Process for Production Thereof In force · High confidence | In force | High confidence | |
| US 9,487,765 | Stabilized Transglutaminase and Process for Production Thereof In force · High confidence | In force | High confidence | |
| US 9,090,886 | Beta-Amylase, Gene Coding Therefor and Manufacturing Method Thereof In force · High confidence | In force | High confidence | |
| US 9,157,074 | Beta-Amylase, Gene Coding Therefor and Manufacturing Method Thereof In force · High confidence | In force | High confidence | |
| US 8,318,223 | Method for Producing Modified Milk held by Ajinomoto Co., Inc. and Amano Enzyme Inc. In force · High confidence | In force | High confidence | |
| US 8,911,984 | Tannase, Gene Encoding Same, and Process for Producing Same In force · High confidence | In force | High confidence | |
| US 8,486,682 | Beta-Amylase, Gene Coding Therefor and Manufacturing Method Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 59: 33 patents ended · 123 applications pending · 44 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.